VieCure secures $43M to expand AI oncology care in communities

VieCure has closed a $43 million funding round to accelerate deployment of its Halo Intelligence™ platform across community oncology practices. The round was led by Mitch Rales (via his investment activity) and Northpond Ventures, with participation from Durable Capital Partners, Socium Ventures (backed by Cox Enterprises) and Sator Grove Holdings. The company said the fresh capital will fund product development, clinic expansion and operational scaling.

The raise comes as community oncology centres—which manage more than 80% of U.S. cancer care—face rising clinical complexity from precision medicine, genomic testing and evolving guideline pathways. VieCure positions Halo as a clinical decision-support layer and purpose-built oncology EMR that fuses structured patient records, AI inference and workflow automation to reduce friction and speed treatment decisions.

Leadership changes underline investor conviction. Founder and CEO Michael Power remains in place, while investor and business-builder Mitch Rales will join the board alongside oncologist and past ASCO president Howard “Skip” Burris III, M.D. VieCure also said it will partner with Mr. Rales’ operational firm, New Bearing, to adopt the New Bearing Foundational Business System and lift operating discipline as the company scales.

Early adopters report measurable clinical impact. VieCure now supports care for nearly 30,000 patients across a growing network of clinics. Customers have seen an approximately 8x increase in tumor sequencing rates and roughly a 2x increase in guideline-compliant treatment plans after rolling out Halo—metrics the company cites as signals that decision support can materially change clinical pathways and downstream diagnostic revenue.

Industry context: data- and workflow-first oncology platforms have drawn strategic interest as life-sciences companies and health systems pursue real-world evidence and precision pathways. Transactions such as the acquisition of oncology data platforms in recent years show the strategic premium on tools that consolidate clinical data, speed trial matching and improve guideline adherence. For community practices, those capabilities are increasingly important as reimbursement models and value-based care push toward measurable outcomes.

Investors framed the round as both a technology and capacity bet. Michael Rubin, M.D., Ph.D., CFA, Founder and CEO of Northpond Ventures, said VieCure’s software can become the conduit for evidence-based oncology in non‑academic settings. Clinicians quoted in the company release, including Ashvini Sengar, M.D., Chief Medical Officer at Alabama Cancer Care, described Halo as central to daily workflows and care coordination.

What to watch next: how the company translates improved sequencing and guideline adherence into measurable outcomes at scale, and whether tighter integration with life-science partners and payers accelerates adoption. For now, VieCure has the capital to extend Halo’s footprint, invest in AI-driven clinical automation, and deepen operational practices under New Bearing guidance—moves that could pressure competitors in the oncology EMR and decision‑support market.